Why seven biotech startups have opted for the SPAC route in 2021

This year is nothing like last year’s SPAC attack — just seven biotech companies have opted for the SPAC route in 2021, by our count — but the fact that companies are still choosing SPACs over IPOs speaks to their continued attractiveness.